Advances in nucleoside monophosphate prodrugs as anti-HCV agents

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 935-950

  Bobeck, Drew R ^a   Schinazi, Raymond F ^b   Coats, Steven J ^a  

^a RFS Pharma LLC   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPYLPENTYL ESTER; 2' C METHYL 4 AZIDOCYTIDINE; 2' C METHYL 4 AZIDOURIDINE; 2' METHYLCYTIDINE; 9 [3 HYDROXYL 2 (PHOSPHONOMETHOXY)PROPYL]ADENINE; ANTIVIRUS AGENT; DOUBLE STRANDED DNA; ESTER DERIVATIVE; HEXADECYLOXY ESTER; HYDROXYPHOSPHORAMIDATE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE MONOPHOSPHATE PRODRUG; NUCLEOSIDE TRIPHOSPHATE; NUCLEOTIDE DERIVATIVE; OCTADECYLOXYETHYL ESTER; PEGINTERFERON ALPHA; PEPTIDOMIMETIC AGENT; PHOSPHONIC ACID DERIVATIVE; PLACEBO; PSI 7851; RIBAVIRIN; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS DNA;

ADENOVIRUS; ANTIVIRAL ACTIVITY; COWPOX VIRUS; CYTOMEGALOVIRUS; CYTOTOXICITY; DNA VIRUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; DRUG TARGETING; ENANTIOMER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; VACCINIA VIRUS;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG EVALUATION; HEPACIVIRUS; HEPATOCYTES; HUMANS; LIVER; NUCLEOSIDES; PRODRUGS;

EID: 78651110499     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1667     Document Type: Review

References (76)

1. Choo QL, Kuo G, Weiner A, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derivied from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359-362. (Pubitemid 19117877)
2. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-1466.
3. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350:1425-1431.
4. Poynard T, Ratziu V, Benhamou Y, Opolon P, Cacoub P, Bedossa P. Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:211-228.
5. Hoofnagle JH, Hepatitis C. The clinical spectrum of disease. Hepatology 1997; 26 Suppl 1:15S-20S.
6. McGuigan C, Perrone P, Madela K, Neyts J. The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus. Bioorg Med Chem Lett 2009; 19:4316-4320.
7. Ghosn J, Larsen C, Piroth L, et al. Evidence for ongoing epidemic sexual transmission of HCV (2006 to 2007) among HIV-1-infected men who have sex with men: France. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 800.
8. Fishman S, Childs K, Dieterich D, et al. Age and risky behaviors of HIV-infected men with acute HCV infection in New York City are similar, but not identical, to those in a European outbreak. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 801.
9. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 2007; 6:991-1000.
10. Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother 2006; 40:74-82.
11. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
12. McCown MF, Rajyaguru S, Pogam Sl, et al. The hepatitis C virus replicon presents a higher barier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52:1604-1612.
13. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
14. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 Suppl 1:S237-S244.
15. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003; 59:1-11. (Pubitemid 36773885)
16. Gordon CP, Keller PA. Control of hepatitis C: a medicinal chemistry perspective. J Med Chem 2005; 48:1-20.
17. Keicher JD, Roberts CD, Dyatkina NB, inventors; Genelabs Technologies, Inc., assignee. Nucleoside compounds for treating viral infections. United States patent US 0107312. 2005 May 19.
18. Wong T, Lee SS. Hepatitis C: a review for primary care physicians. Can Med Assoc J 2006; 174:649-659.
19. Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007; 7:1302-1329. (Pubitemid 47321576)
20. Prakash TP, Prhavc M, Eldrup AB, et al. Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5′-monophosphates as inhibitors of hepatitis C virus RNA replication. J Med Chem 2005; 48:1199-1210.
21. Arends JE, Mudrikova T, Wensing AMJ, et al. High percentage of non-response with peginterferon-alfa-2a monotherapy for the treatment of acute hepatitis C in HIV infected patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12-15 September 2009, San Francisco, CA, USA. Abstract H-222.
22. De Francesco R, Migliaccia G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436:953-960.
23. Huang Z, Murray MG, Secrist JA, III. Recent development of therapeutics for chronic HCV infection. Antiviral Res 2006; 71:351-362.
24. Meppen M, Pacini B, Bazzo R, et al. Cyclic phosphoramidates as prodrugs of 2′-methylcytidine. Eur J Med Chem 2009; 44:3765-3770.
25. Martin LT, Cretton-scott E, Placidi L, et al. In vitro and in vivo metabolism and pharmacokinetics of bis[(t-butyl)- S-acyl-2-thioethyl]-β-L- 2′,3′-dideoxy-5-fluorocytidine monophosphate. Nucleosides Nucleotides Nucleic Acids 2000; 19:481-499.
26. Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994; 140:1-22.
27. Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. J Med Chem 2008; 51:2328-2345.
28. De Clercq E, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006; 147:1-11.
29. Poijärvi-Virta P, Lönnberg H. Prodrug approaches of nucleotides and oligonucleotides. Curr Med Chem 2006; 13:3441-3465.
30. Li F, Maag H, Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 2008; 97:1109-1134.
31. Ploss A, Khetani SR, Jones CT, et al. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A 2010; 107:3141-3145.
32. Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ. Approaches for the development of antiviral compounds: the case of hepatitis C virus. Handb Exp Pharmacol 2009; 189:25-51.
33. Devine KG, McGuigan C, O'Connor TJ, Nicholls SR, Kinchington D. Novel phosphate derivatives of zidovudine as anti-HIV compounds. AIDS 1990; 4:371-373.
34. Cahard D, McGuigan C, Balzarini J. Aryloxy phosphoramidate triesters as Pro-Tides. Mini Rev Med Chem 2004; 4:371-381.
35. Pierra C, Amador A, Benzaria S, et al. Synthesis and pharmacokinetics of valopictabine (NM-283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 2006; 49:6614-6620.
36. Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of β-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007; 51:503-509. (Pubitemid 46185267)
37. Gardelli C, Attenni B, Donghi M, et al. Phosphoramidate prodrugs of 2′-methylcytidine for therapy of hepatitus C virus infection. J Med Chem 2009; 52:5394-5407.
38. Perrone P, Luoni GM, Kelleher MR, et al. Application of the phosphoramidate protide approach to 4′-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive Nucleoside. J Med Chem 2007; 50:1840-1849.
39. Rondla R, Coats SJ, McBrayer TR, et al. Anti-hepatitis C virus activity of novel β-D-2′-C-methyl-4′-azido pyrimidine nucleoside phosphoramidate prodrugs. Antivir Chem Chemother 2009; 20:99-106.
40. Sofia MJ, Du J, Wang P, Nagarathnam D, inventors; Pharmasset, Inc., assignee. Nucleoside phosphoramidate prodrugs. WO 121634. 2008 October 9.
41. Lawitz E, Rodriguez-Torres M, Denning J, et al. Potent antiviral activity observed with PSI-7851, a novel nucleotide polymerase inhibitor for HCV, following multiple ascending oral doses for 3 days in patients with chronic HCV infection. Global Antiviral Journal 2009; 5 Suppl 1:96.
42. Lam AM, Espiritu C, Micolochick Steuer HM. In vitro selection and characterization of hepatitis C virus replicon variants resistant to PSI-7851, a phosphoramidate prodrug of β-D-2′-deoxy-2′-fluoro-2′-C- methyluridine monophosphate. Global Antiviral Journal 2009; 5 Suppl 1:137-138.
43. Ludmerer SW, Graham DJ, Boots E, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005; 49:2059-2069.
44. Murakami E, Tolstykh T, Bao H, Niu C, Furman PA. Mechanism of PSI-7851 activation. Global Antiviral Journal 2009; 5 Suppl 1:96-97.
45. Patti J, Ames B, Bryant D, et al. Pharmacological properties and in vitro characterization of INX-189, a liver targeted phosphoramidate nucleoside analogue inhibitor of NS5b. 60th Annual Meeting of the American Association for the Study of Liver Diseases. 30 October-3 November 2009, Boston, MA, USA. Poster 1611.
46. Kolykhalov A, Chamberlain S, Gorovits E, et al. In vitro characterization of INX-189, a highly potent phosphoramidate nucleoside analogue inhibitor of HCV. Global Antiviral Journal 2009; 5 Suppl 1:95.
47. Perrone P, Daverio F, Valente R, et al. First example of phosphoramidate approach applied to a 4′-substituted purine nucleoside (4′-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J Med Chem 2007; 50:5463-5470.
48. Gunic E, Suetying C, Frank R, et al. 6-Hydrazinopurine 2′-methyl ribonucleosides and their 5′-monophsophate prodrugs as potent hepatitis C virus inhibitors. Bioorg Med Chem Lett 2007; 17:2456-2458. (Pubitemid 46507790)
49. Donghi M, Attenni B, Gardelli C, et al. Synthesis and evaluation of novel phosphoramidate prodrugs of 2′-methylcytidine as inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2009; 19:1392-1395.
50. Meppen M, Narjes F, Pacini B, Gardelli C, Durette PJ, inventors; Merck & Co., Inc., Instituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A., assignees. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection. WO 079206. 2008 July 3.
51. Eckstein F, Gish G. Phosphorothioates in molecular biology. Trends Biochem Sci 1989; 14:97-100.
52. Périgaud C, Gosselin G, Lefebvre I, et al. Rational design for cytosolic delivery of nucleoside monphosphates: 'SATE' and 'DTE' as enzyme-labile transient phosphate protecting groups. Bioorg Med Chem Lett 1993; 3:2521-2526.
53. Benzaria S, Bardiot D, Bouisset T, et al. 2′-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication. Antivir Chem Chemother 2007; 18:225-242.
54. Butler T, Cho A, Kim C, Saunders OL, Zhang L, inventors; Gilead Sciences, Inc., assignee. 1′-Substituted carbanucleoside analogs for antiviral treatment. WO 132135. 2009 October 29.
55. Cho A, Kim C, Parrish J, Xu J, inventors; Gilead Sciences, Inc., assignee. Carba-nucleoside analogs for antiviral treatment. WO 132123. 2009 October 29.
56. Ding Y, Girardet J, Hong Z, et al. Synthesis of 9-(2-β-C-methyl- β-D-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication. Bioorg Med Chem Lett 2005; 15:709-713. (Pubitemid 40143152)
57. Gunic E, Girardet JL, Ramasamy K, et al. Cyclic monophosphate prodrugs of base-modified 2′-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg Med Chem Lett 2007; 17:2452-2455.
58. Sommadossi JP, Gosselin G, Pierra C, Perigaud C, Peyrottes S, inventors; Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique, L'Universite Montpellier Il., assignees. Compounds and pharmaceutical compositions for the treatment of viral infections. WO 082601. 2008 July 10.
59. Standring DN, Perigaud C, Peyrottes S, et al. Pharmacology of IDX184, a liver-targeting nucleotide prodrug for the treatment of HCV. Global Antiviral Journal 2009; 5 Suppl 1:22.
60. Lalezari J, Asmuth D, Casir A, et al. Antiviral activity, safety and pharmacokinetics of IDX184, a liver - targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. 60th Annual Meeting of the American Association for the Study of Liver Diseases. 30 October-2 November 2009, Boston, MA, USA. Poster LB18.
61. Mayers D. IDX184 - a novel, liver-targeted, once-a-day nucleoside prodrug for the treatment of chronic HCV infection. HEP DART - Frontiers in Drug Development for Viral Hepatitis. Satellite Mini-Symposium: Toward Curative Therapies for Hepatitis C. 6-10 December 2009, Kohala Coast, HI, USA.
62. Erion MD, Bullough DA, Lin C-C, Hong Z. HepDirect PDs for targeting nucleotide-based antiviral drugs to the liver. Curr Opin Investig Drugs 2006; 7:109-117.
63. Bookser BC, Raffaele NB. High-throughput synthesis of HepDirect prodrugs of nucleoside monophosphates. J Comb Chem 2008; 10:567-572.
64. 450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based prodrugs to the liver. J Am Chem Soc 2004; 126:5154-5163.
65. Hecker SJ, Reddy KR, van Poelje PD, et al. Liver-targeted prodrugs of 2′-methyladenosine for therapy of hepatitus C virus infection. J Med Chem 2007; 50:3891-3896.
66. Hecker SJ, Reddy KR, inventors; Metabasis Therapeutics, Inc. assignee. Nucleoside prodrugs and uses thereof. WO 073506. 2009 June 11.
67. Bookser BC, Hecker SJ, Reddy RK, Smith DB, Sun Z, inventors; Metabasis Therapeutics Inc., assignee. Antiviral nucleoside compounds. WO 069095. 2009 June 4.
68. Hecker SJ, Reddy KR, Sun Z, Bookser BC, Smith DB. inventors; Roche Palo Alto LLC, assignee. Nucleoside prodrugs and uses thereof. United States patent US 0209481. 2009 August 20.
69. Wyles DL, Kaihara KA, Korba BE, Schooley RT, Beadle JR, Hostetler KY. The octadecylonyethyl ester of (S)-9-[3- hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother 2009; 53:2660-2662.
70. Morrey JD, Korba BE, Beadle JR, Wyles DL, Hostetler KY. Alkoxyalkyl esters of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo. Antimicrob Agents Chemother 2009; 53:2865-2870.
71. Standring D. IDX184, a liver-targeted nucleotide prodrug for the treatment of HCV. HEP DART - Frontiers in Drug Development for Viral Hepatitis. Satellite Mini-Symposium: Toward Curative Therapies for Hepatitis C. 6-10 December 2009, Kohala Coast, HI, USA.
72. Pharmasset, Inc. Pharmasset: building for success. 28th Annual JPMorgan Healthcare Conference. 11-14 January 2010, San Francisco, CA, USA. (Accessed 2 March 2010.) Available from http://files.shareholder.com/downloads/VRUS/ 733159221x0x344081/b202fb5f-894f-40a0-aa38-abffea446aca/ VRUS%20JPM%20Pres%20011410.pdf
73. Burton Jr., JR, Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis 2009; 13:453-465.
74. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007; 6:991-1000.
75. Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat 2010; 17:77-90.
76. McGuigan C, Perrone P, inventors; University College Cardiff Consultants Limited, KU Leuven Research and Development, assignees. Chemical Compounds. WO 062206. 2008 May 29.